AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) for an additional indication.
Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).
The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
WALK-IN DRIVE – FRESHERS | PRODUCTION 🚨 Aspiro Pharma, a leading USFDA-approved pharmaceutical company, is…
Infinium Pharmachem Limited is hiring for two trainee positions at their Sojitra GIDC, Anand, Gujarat…
We at Marksans Pharma Limited, Goa Hiring for following positions: Department- Warehouse Section- RM/PM Dispensing…
WE ARE HIRING | PENAM BIOSCEINCES PRIVATE LIMITED Are you looking for your next career…
We're Hiring for Freshers | West Coast Pharmaceuticals 🎓 Qualification: B.Pharm / M.Pharm + MBA…
WE ARE HIRING | QC CHEMIST / OFFICER 🚨 🌿 Windlas Biotech Limited is looking…